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not economically important. HFS very rarely lead to hospi-
talization (0.7%) and was generally effectively managed by
dose interruption or appropriate dose reduction and patient
education. CONCLUSION: Treatment with capecitabine
avoided 57 hospital days per 100 patients and reduced use
of high-cost medications for AEs by 56% compared to M-
regimen. Reduction in hospitalization observed in this trial
would result in savings in the range of €17,000–€29,000
(depending on country) per 100 patients. AE profiles of dif-
ferent regimens are likely to be important economic factors
in oncology. Stomatitis, infection/sepsis and neutropenia
are of particularly high economic relevance.
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OBJECTIVES: To assess whether different methods of
asking for the willingness to pay (WTP) lead to different
outcomes. METHODS: Sixty people from the general
population were asked for their WTP for a new drug re-
lieving breakthrough cancer pain by a trained interviewer.
All the individuals answered WTP questions posed in
three different randomized ways with the open-card method.
First, they gave their WTP as patients, under certainty of
needing the drug (use or consumption value of the good).
Second, they gave their WTP for a private insurance (op-
tion value) given a probability of 10% of needing the
drug one day. Last, they gave their WTP as contributors
by paying taxes (existence value). The hypothesis of the
research was that the role adopted by the respondent in
the hypothetical situation described for each method in-
fluences results. We expected the WTP for the drug with
the simple method (under certainty) to be lower than the
WTP with the private insurance method and the latter to
be lower than the WTP with the contributor method, as
the different values of the good should be cumulative.
RESULTS: The duration of the interview was between 20
and 25 minutes. Data analysis showed that the different
methods have an influence on the WTP for the drug and
that certain sociodemographic characteristics of the indi-
viduals have an impact on study results. The relevance of
the differences found will be discussed during the presen-
tation. CONCLUSIONS: Different methods of asking for
the WTP lead to differences in outcomes.
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OBJECTIVE: To compare the Quality of Life (QoL) in-
dexes of received two different schemes of chemotherapy
patients in advanced breast cancer. METHODS: Patients
were assigned to chemotherapy. Arm A: standard scheme
CAF (23 pts.), and arm B: included docetaxel scheme
TAD (23 pts.). The instrument for QoL assessment was
FACT-Taxane (Functional Assessment of Cancer Ther-
apy for patients with Taxane toxicity). The questionnaire
consists from 43 questions, 27 of them are general ques-
tions and 16 are questions concerning toxicity reactions
of patients. The patients should answer the questions of
the questionnaire before the treatment, after 3rd and 6th
cycles of chemotherapy. RESULTS: According to re-
ceived data toxicity reactions were more pointed for
TAD scheme than for CAF scheme. The mediana of util-
ity indexes was 57.6 and 51.0 respectively after the 6th
cycle for additional (specific for Taxane) questions. But
the general utility index for arm B was higher than for
arm A, 112 and 109 respectively. CONCLUSION: In
Russia the most limiting factors of docetaxel usage are
related to cost and toxicity issues. In this study we receive
reliable evidence that docetaxel toxicity doesn’t influence
general QoL of the patients. Also in spite of toxicity reac-
tions the QoL of docetaxel treated patients was higher
than standard scheme treated patients. 
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OBJECTIVE: As the US population ages, the increasing
prevalence of cancer is likely to result in higher direct
medical and non-medical costs. While estimates of can-
cer-related direct medical costs exist, very little informa-
tion is available regarding family caregiving costs for eld-
erly cancer patients. Our objective was to determine valid
and generalizable estimates of family caregiving costs for
elderly cancer patients in the US. METHODS: We used
data from the first wave (1993) of the Asset and Health
Dynamics (AHEAD) Study, a nationally representative
longitudinal survey of people aged 70 or older living in
the community. We used a multivariable two-part regres-
sion model to control for differences in health status, so-
cial support, and sociodemographics. The adjusted prob-
ability of receiving family care, the adjusted average
weekly number of caregiving hours, and the average an-
nual caregiving cost per case (assuming an average hourly
wage of $8.30) was estimated for these three groups. RE-
SULTS: Of the 7443 subjects surveyed, 6422 (86%) re-
ported no history of cancer (No Ca), 718 (10%) reported
having a diagnosis of cancer but not receiving treatment
for their cancer in the last year (Ca/No Tx) and 303 (4%)
reported receiving treatment for their cancer in the last
